Connor, Clark & Lunn Investment Management Ltd. Nuvalent, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $22 Billion
- Q2 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 44,414 shares of NUVL stock, worth $4.54 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
44,414
Previous 19,217
131.12%
Holding current value
$4.54 Million
Previous $1.44 Million
133.47%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
178Shares Held
56.6MCall Options Held
527KPut Options Held
131K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$2.05 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$468 Million14.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.78MShares$386 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$309 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$276 Million41.86% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.4B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...